ReviewExpert opinion on drug delivery2010
Drug delivery by red blood cells: vascular carriers designed by mother nature.
Review in Expert opinion on drug delivery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 387 citations in OpenAlex.
- Shear-Responsive Red Blood Cell Carriers for Targeted Drug Delivery to Constricted Arteries.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems.Advanced drug delivery reviews · 2026Review
- Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle.Materials today. Bio · 2026Review
- In vivo metabolic tagging and targeting of circulating red blood cells.Nature communications · 2026Article
- Beyond autologousMolecular therapy. Oncology · 2026Review
- Blood Cell-Based Drug Delivery Systems: From Biological and Mechanical Design to Clinical Applications.Bioengineering (Basel, Switzerland) · 2026Review
- Equip your vehicle for the right terrain: Using features of local pathology to guide engineering of targeted drug delivery systems.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Cell- and biological-based drug delivery vectors for cancer treatment.Frontiers in molecular biosciences · 2026Review
- Seeing What Sticks: Anchoring Capabilities of Moieties for Use in Cell-Conveyed Therapeutics.Bioconjugate chemistry · 2025Article
- Article
- Pharmacokinetic Assessment of Drug Efflux from Erythrocytes Loaded with Corticosteroid Esters.Pharmaceutical research · 2025Article
- NMR Assessment of the High Order Structure of Biological Therapeutics in Erythrocytes Provides a Tool for Drug Delivery Design.Journal of the American Chemical Society · 2025Article
- Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside.Molecular cancer · 2025Review
- A Microfluidic Approach for Intracellular Delivery into Red Blood Cells: A Deeper Understanding of the Role of Chemical/Rheological Properties of the Cellular Suspension.Annals of biomedical engineering · 2025Article
- Numerical Simulation in Microvessels for the Design of Drug Carriers with the Immersed Boundary-Lattice Boltzmann Method.Micromachines · 2025Article
- Article
- Trojan Horse Delivery Strategies of Natural Medicine Monomers: Challenges and Limitations in Improving Brain Targeting.Pharmaceutics · 2025Review
- Photothrombolytics: A light-driven technology for the targeted lysis of thrombi.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Investigation on the Interaction of Dendritic Core Multi-Shell Nanoparticles with Human Red Blood Cells.Nanomaterials (Basel, Switzerland) · 2025Article
- Current Trends in Nanotechnology-Based Drug Delivery Systems for the Diagnosis and Treatment of Malaria: A Review.Current drug delivery · 2025Review
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
Abstract
importance of the fieldVascular delivery of several classes of therapeutic agents may benefit from carriage by red blood cells (RBC), for example, drugs that require delivery into phagocytic cells and those that must act within the vascular lumen. The fact that several protocols of infusion of RBC-encapsulated drugs are now being explored in patients illustrates a high biomedical importance for the field. AREAS COVERED BY THIS REVIEW: Two strategies for RBC drug delivery are discussed: encapsulation into isolated RBC ex vivo followed by infusion in compatible recipients and coupling therapeutics to the surface of RBC. Studies of pharmacokinetics and effects in animal models and in human studies of diverse therapeutic enzymes, antibiotics and other drugs encapsulated in RBC are described and critically analyzed. Coupling to RBC surface of compounds regulating immune response and complement, affinity ligands, polyethylene glycol alleviating immune response to donor RBC and fibrinolytic plasminogen activators are described. Also described is a new, translation-prone approach for RBC drug delivery by injection of therapeutics conjugated with fragments of antibodies providing safe anchoring of cargoes to circulating RBC, without need for ex vivo modification and infusion of RBC. WHAT THE READER WILL GAIN: Readers will gain historical perspective, current status, challenges and perspectives of medical applications of RBC for drug delivery. TAKE HOME MESSAGE: RBC represent naturally designed carriers for intravascular drug delivery, characterized by unique longevity in the bloodstream, biocompatibility and safe physiological mechanisms for metabolism. New approaches for encapsulating drugs into RBC and coupling to RBC surface provide promising avenues for safe and widely useful improvement of drug delivery in the vascular system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.